Targeting mitochondrial metabolism by the mitotoxin bromoxib in leukemia and lymphoma cells

Area of Science:

• Biochemistry
• Pharmacology
• Cell Biology

Background:

• Targeting cancer cell metabolism is a key therapeutic strategy.
• Natural compounds offer potential for novel anti-cancer drug development.
• Mitochondrial dysfunction plays a critical role in cancer progression.

Purpose of the Study:

• To investigate the anti-cancer potential of bromoxib, a natural compound from the marine sponge Dysidea family.
• To elucidate the mechanisms underlying bromoxib's cytotoxic effects.
• To evaluate bromoxib's impact on cancer cell metabolism and apoptosis.

Main Methods:

• Cytotoxicity assays in various human cancer cell lines (leukemia, lymphoma, glioblastoma).
• Mitochondrial pathway activation analysis (Bax translocation, Smac release).
• Assessment of apoptosis inhibition (caspase 9 deficiency, Bcl-2 overexpression).
• Mitochondrial membrane potential (ΔΨm) dissipation and mitochondrial fragmentation studies.
• Analysis of ATP production via glycolysis and oxidative phosphorylation (OXPHOS).

Main Results:

• Bromoxib exhibited significant cytotoxicity against leukemia, lymphoma, and solid tumor cell lines.
• Bromoxib induced apoptosis via the mitochondrial death pathway, involving Bax translocation and Smac release.
• Apoptosis induction was confirmed by its blockage in caspase 9 deficient and Bcl-2 overexpressing cells.
• Bromoxib uncoupled the electron transport chain, dissipating mitochondrial membrane potential and causing mitochondrial fragmentation.
• Bromoxib inhibited ATP production from both glycolysis and OXPHOS by targeting key electron transport chain complexes.

Conclusions:

• Bromoxib demonstrates potent anti-cancer activity across multiple cancer types.
• Its mechanism involves the induction of apoptosis and disruption of cellular energy metabolism.
• Bromoxib's dual action on glycolysis and mitochondrial respiration makes it a promising candidate for treating leukemia and lymphoma.